XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disaggregation of Revenue [Line Items]        
Total revenue $ 50,641 $ 44,319 $ 106,544 $ 80,480
License Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenue 0 1,000 0 7,000
Development Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenue 269 5,158 1,147 9,050
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]        
Disaggregation of Revenue [Line Items]        
Total revenue 318 1,806 606 3,335
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]        
Disaggregation of Revenue [Line Items]        
Total revenue $ (50) $ 2,273 $ 418 $ 4,305